Inhibition of DC-CIK VISTA signal for improving the anti-tumor effect of malignant tumor cells

doi:10.3969/j.issn.1673-8640.2018.10.015

Abstract

Abstract:

Objective To inhibit the antigen of anti-V-domain Ig suppressor of T cell activation（VISTA） antibody on dendritic cell-cytokine-induced killer cell（DC-CIK） and the down regulation due to VISTA signal activation,and to evaluate the anti-tumor effect of malignant tumor cells. Methods Anti-VISTA antibody on DC-CIK was determined by flow cytometry. The killing activity of DC-CIK on human chronic myeloid leukemia cell line K562 was analyzed by 3-（4,5-dimethylthiazol-2-yl）-2,5-diphenyltetrazolium bromide（MTT）. The effect of anti-VISTA antibody on the proliferation and differentiation of DC-CIK was analyzed by cell count analysis and flow cytometry,respectively. Results After the incubation of mature DC-CIK with anti-VISTA antibody,the percentage of anti-VISTA antibody positive cells was（10.26±0.57）%. With the increasing of effector cells（DC-CIK）-to-target cells（K562） ratio,the killing activities in experimental group（DC-CIK cell treated with anti-VISTA antibody） and control group（untreated DC-CIK cell） were increased. When effector cells-to-target cells ratios of 10∶1 and 20∶1,the killing activities in experimental group were（77.3±6.8）% and（92.8±5.9）%,respectively,which were higher than those in control group [（64.8±4.0）% and（81.8±5.4）%]（P<0.01）. After incubation for 54 h,the cell number of experimental group was 1.35-time higher than that of control group（P<0.01）. The percentage of CD3⁺CD56⁺ natural killer T cells（NKT） in experimental group [（35.12±2.13）%] was higher than that in control group [（21.35±1.32）%]（P<0.01）. Conclusions The inhibition of DC-CIK VISTA signal can improve the anti-tumor effect of malignant tumor cells through the proliferation and differentiation of DC-CIK.

Key words: Dendritic cell-cytokine-induced killer cell, V-domain Ig suppressor of T cell activation, Proliferation, Differentiation, Immune escape

CLC Number:

R446.61

YANG Huikuan, YUAN Zhaohu, CHEN Xiaojie, WEI Yaming, CHEN Dandan. Inhibition of DC-CIK VISTA signal for improving the anti-tumor effect of malignant tumor cells[J]. Laboratory Medicine, 2018, 33(10): 933-937.

Figures/Tables 3

References 10

[1]	LINES J L,PANTAZI E,MAK J,et al.VISTA is an immune checkpoint molecule for human T cells[J]. Cancer Res,2014,74(7):1924-1932.
[2]	LE MERCIER I,CHEN W,LINES J L,et al.VISTA regulates the development of protective antitumor immunity[J]. Cancer Res,2014,74(7):1933-1944.
[3]	WANG L,LE MERCIER I,PUTRA J,et al.Disruption of the immune-checkpoint VISTA gene imparts a proinflammatory phenotype with predisposition to the development of autoimmunity[J]. Proc Natl Acad Sci U S A,2014,111(41):14846-14851.
[4]	GELLER M A,MILLER J S.Use of allogeneic NK cells for cancer immunotherapy[J]. Immunotherapy,2011,3(12):1445-1459.
[5]	李翠,施幼豪,吴江南,等. 不明原因反复自然流产患者免疫治疗前后外周血CD4+CD25+CD127lowT细胞百分率的分析[J]. 检验医学,2017,32(1):14-17.
[6]	GUBIN M M,ZHANG X,SCHUSTER H,et al.Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens[J]. Nature,2014,515(7528):577-581.
[7]	TURCOTTE S,ROSENBERG S A.Immunotherapy for metastatic solid cancers[J]. Adv Surg,2011,45:341-360.
[8]	YUANYING Y,LIZHI N,FENG M,et al.Therapeutic outcomes of combining cryotherapy,chemotherapy and DC-CIK immunotherapy in the treatment of metastatic non-small cell lung cancer[J]. Cryobiology,2013,67(2):235-240.
[9]	RABE H,NORDSTRÖM I,ANDERSSON K,et al. Staphylococcus aureus convert neonatal conventional CD4(+) T cells into FOXP3(+) CD25(+) CD127(low) T cells via the PD-1/PD-L1 axis[J]. Immunology,2014,141(3):467-481.
[10]	ROSENBERG S A,YANG J C,SHERRY R M,et al.Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy[J]. Clin Cancer Res,2011,17(13):4550-4557.

[1]	WANG Rong, XING Lianxiang, HUANG Keliang, LI Xin. MiR-374 promoting proliferation and invasion of breast cancer cells by targeting and down-regulating TRIM35 [J]. Laboratory Medicine, 2023, 38(9): 812-817.
[2]	YANG Yuqiang, QUAN Xiaoli, WANG Liuyu, XIAN Wenfeng, YANG Hong. Expression of RRBP1 in osteosarcoma tissues and its effect on cell biological characteristics [J]. Laboratory Medicine, 2023, 38(9): 842-848.
[3]	ZHANG Ying, JING Lijuan, LI Li. Relationship between the expression of miR-138 in peripheral blood mononuclear cells of hepatitis B virus proliferation in carriers [J]. Laboratory Medicine, 2023, 38(6): 559-562.
[4]	SHANG Zhenjun, WEI Wei, LIU Ruihan. Effect of inhibiting PTBP1 on the proliferation and invasiveness of choroidal melanoma cells [J]. Laboratory Medicine, 2023, 38(1): 51-55.
[5]	JI Ye, YUAN Xiaosun, ZHANG Lei, MA Huili, XUE Yongfei, LI Changsheng, ZHANG Jingwei, REN Zhonghai, ZHANG Tengfei. Expression of lncRNA HULC in papillary thyroid carcinoma tissues [J]. Laboratory Medicine, 2022, 37(7): 605-609.
[6]	YANG Meng, DING Hui. Role of miR-19b in human aortic valve interstitial cell calcification [J]. Laboratory Medicine, 2022, 37(5): 466-471.
[7]	CHEN Si, LIU Hua, LIU Yiwen, HE Yiqing, ZHANG Guoliang, YANG Cuixia, DU Yan, GAO Feng. Clinical significance of combined determination of serum HER-2 and CD44 in colorectal cancer [J]. Laboratory Medicine, 2022, 37(4): 336-341.
[8]	ZHAO Mingna, ZHANG Chenzi, HONG Qiushuang, LOU Jiatao. Mechanism of IL-8/miR-182 positive feedback regulatory axis in non-small cell lung cancer [J]. Laboratory Medicine, 2022, 37(4): 349-355.
[9]	LI Mingwu, WANG Qinzhi, SUN Farui. Influence of MUC16 on the cell proliferation and invasion of osteosarcoma cells [J]. Laboratory Medicine, 2022, 37(10): 979-983.
[10]	YU Ying, LI Jianjie, LI Hanhua, HUANG Juan, WENG Wenhao, CHEN Xuefei. Inhibit miR-4429 proliferation,migration and invasion of prostate cancer cells by targeting metadherin [J]. Laboratory Medicine, 2021, 36(12): 1267-1273.
[11]	HU Yuyi, CHEN Pu, GUO Wei, PAN Baishen. Research progress of myeloid differentiation factor 88 polymorphism [J]. Laboratory Medicine, 2020, 35(4): 380-386.
[12]	ZHANG Xiaoying. Relationship between the changes of TK1 and ID-1 levels and curative effect in cervical cancer patients before and after neoadjuvant chemotherapy [J]. Laboratory Medicine, 2020, 35(2): 108-111.
[13]	HUAN Yu, CAI Xushan, JIAO Jiajun, WU Junlu, QUAN Wenqiang, ZHANG Chunli, XI Fang. Expression of Beclin 1 in breast invasive ductal carcinoma and its relationship with Ki67 [J]. Laboratory Medicine, 2019, 34(7): 595-599.
[14]	LIANG Qiuli, CHENG Jinke, ZUO Yong. ATRA for promoting brown adipogenesis in C3H10T1/2 mesenchymal stem cells [J]. Laboratory Medicine, 2019, 34(5): 451-456.
[15]	XIE Zejin, WANG Houzhao, LIN Yi. CD62p,IL-6 and hs-CRP levels in rheumatoid arthritis [J]. Laboratory Medicine, 2017, 32(11): 966-969.